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PLA2G7a b s t r a c t
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays a strong role in the occurrence of
certain cardiovascular disease processes. Polymorphisms at the protein level are also estimated to corre-
late with increased risk factors for heart attacks. One such polymorphism is the V279F polymorphism in
Lp-PLA2 which results in a change in enzyme performance capability. This in turn implies a reduced risk
of acute myocardial infarct (AMI) in Korean and Indonesian subpopulations.
Aim: This study aimed to analyze changes in protein properties, structure, energy stability, epitope, and
immunogenicity that are due to the substitution of the Valine (V) amino acid at position 279 to
Phenylalanine (F) in the Lp-PLA2 protein.
Methodology: The role of Lp-PLA2 in the cardiovascular process and in AMI was analyzed based on the
protein-protein network according to the BioGRID, MENTHA, and STRING databases. Protein properties
and energy stability were examined by FoldX; this was followed by identification of epitope using
ElliPro. The immunogenicity was evaluated in vivo by injecting the protein into mice and subsequently
measuring their antibody production using the ELISA technique.
Results: The substitution of Valine for Phenylalanine was predicted to increase protein stability and epi-
tope shifts. Further studies on animal experiments exhibit that the 279V variant is able to induce IgG pro-
duction better than the 279F variant.
Conclusion: Based on these data, it can be concluded that the V279F polymorphism influences the surface
structure, energy stability, epitope and immunogenicity of the Lp-PLA2 protein. The changes in the
immunogenicity and epitope shift indicated that the protein is valuable as a biomarker for use in acute
myocardial infarct. The results of this study provide an opportunity to develop monoclonal antibodies
that are specifically able to identify V279F polymorphisms as a predictor of the risk of acute myocardial
infarct.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The PLA2G7 gene encodes the Lipoprotein-associated phospho-
lipase A2 (Lp-PLA2) protein, an enzyme of the phospholipase A2
family [1,2] that can degrade oxidized lipids, presumably having
an anti-inflammatory enzymatic role [3]. This protein can also
reduce the inflammatory response because it is able to normalizethe monocyte chemoattractant [2]. However, some reports suggest
that this protein is involved in increased inflammation and miner-
alization in interstitial valve cells [4]. In addition, this protein acts
as an enzyme that hydrolyses platelet activating factor and pro-
duces atherogenic pro-inflammatory compounds that can affect
the risk of cardiovascular disease occurrence. Thus, Lp-PLA2 pro-
tein is thought to act as a risk factor for coronary heart disease
[5–7], especially in cases of thickening of carotid intimal media
[8]. Until recently, there was much debate on whether this protein
serves as a pro or anti-inflammatory agent. The role of this essen-
tial protein could potentially be developed as a marker for
atherosclerosis diagnosis [3,9,10].
108 Widodo et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 107–112In addition to Lp-PLA2 activity that affects the occurrence of
cardiovascular disease, polymorphisms in these proteins also con-
tribute to increased risk factors for atherosclerosis or acute
myocardial infarct [11–13]. Several studies have reported the pres-
ence of polymorphisms in Lp-PLA2 proteins, including A379V,
V279F, and R92H [14,5,15]. The A379V variant of the Lp-PLA2 pro-
tein is thought to be associated with ischemic stroke in Han ethnic,
China [16]. Generally, genetic variation in the PLA2G7 gene is asso-
ciated with subclinical manifestations of coronary atherosclerosis.
This phenomenon shows a very close relationship between Lp-
PLA2 with atherosclerosis in humans, which strongly suggests
the use of Lp-PLA2 as a cardiovascular occurrence biomarker [17].
The 279th amino acid change from Valine to Phenylalanine
(V279F) on Lp-PLA2 protein is predicted to decrease enzymatic
activity due to changes in ‘‘folding kinetics” and its substrate bind-
ing site [18]. Clinical studies suggest that this mutation is thought
to be a risk factor for various inflammatory diseases [19–21]. How-
ever, several other studies have shown that this mutation reduces
the risk of acute myocardial infarct (AMI) in Korean and Indonesian
populations [22]. Given the importance of the Lp-PLA2 function,
this study was conducted to perform in depth analysis of its prop-
erties, structure, epitope, and immunogenicity which may change
as a result of the V279F polymorphism. This information is essen-
tial for further studies in developing monoclonal antibodies that
specifically identify both variants for early detection of AMI risk
factor.2. Research method
2.1. Analysis of the protein network and biological processes
Determining the function of Lp-PLA2 in a biological process is
crucial to understanding the protein’s role in the cardiovascular
process and in the development of AMI. The role of the protein in
the biological process was examined through the interaction of
Lp-PLA2 with other proteins in the cell, based on protein networks.
The protein network of Lp-PLA2 was constructed based on three
databases, i.e., BioGRID, MENTHA, and STRING [23–25]. The data
from the protein network was then used for mapping the role of
Lp-PLA2 in a biological process using Cytoscape software. This
analysis has often been used as a valid tool for understanding the
protein’s role in various mechanisms and pathways within cells
[26].2.2. Analysis of Lp-PLA2 protein V279F properties and structure
The 279th amino acid change from Valine to Phenylalanine
(V279F) in Lp-PLA2 protein is predicted to cause differences in
the properties and surface of the protein. Therefore, analysis of
hydrophobicity, energy stability, mass and accessible surface area
of both variants of this protein was performed. The three-
dimensional model of the 279F variance of Lp-PLA2 was con-
structed using the FoldX software based on the 279V variance of
Lp-PLA2 as a template (PDB access code: 5lp1) [27]. Next, the FoldX
[28] in Yasara software [29] were used to analyze the protein prop-
erties and surface structures of both variants.
The changing amino acids of the V279F polymorphism in the
Lp-PLA2 protein are highly likely to cause the changes in surface
structure and protein properties that may affect epitope shifts. To
anticipate these predictions, ‘‘epitope mapping” analysis was then
performed based on the three-dimensional structure of the Lp-
PLA2 protein in both 279V and 279F variants. This analysis was
conducted using the ‘‘epitope mapping” software based on a 3D
structure, ElliPro [30]. Epitope prediction results were then further
analyzed by comparing the position of the present epitope in bothprotein variants. Protein mapping was performed to determine the
existence of a specific epitope for each protein variant. This analy-
sis is particularly important in support of further investigations to
identify specific epitopes, especially in developing monoclonal
antibodies that are able to recognize both variants of the Lp-PLA2
protein specifically. These monoclonal antibodies can then be
employed to mitigate the risk of early AMI based on Lp-PLA2 pro-
tein polymorphism.
2.3. Immunoprecipitation and SDS-PAGE
Variations in protein are thought to alter the properties, struc-
ture, epitope, and immunogenicity of the protein. To date, these
studies have proven whether the V279F variation of Lp-PLA2 pro-
tein possesses different capabilities in inducing immune system in
mice on producing IgG. Both variants of these proteins were iso-
lated from serum of AMI patients with immunoprecipitation meth-
ods. Immunoprecipitation was then performed as follows, 50 ul
serum was added to 2 ul mouse IgG anti-Lp-PLA2 (RnD system,
AF5106). Then, the solution was added PBS (Bio-Rad, 161-0780)
up to 100 ul, incubated for one hour at 4 C, followed by addition
of 20 ul A/G PLUS-Agarose bead (Santa Cruz Biotechnology) and
incubated overnight at 4 C. The protein was centrifuged at
10,000 rpm for 10 min at 4 C. The pellets were washed using
PBS 3x, then were resuspended in 100 ul elution buffer (0.1 M
glycine-HCl, pH 2.7) (Bio-Rad) to separate antigen and antibody.
After centrifugation at 10,000 rpm for 10 min at 4 C, the super-
natant that contains the target protein was then checked by SDS-
PAGE [31]. The AMI patients were diagnosed using thrombolysis.
The levels of cardiac enzymes such as CPK, CK-MB, and troponin
I were measured and showed an increase in the first 6 h after
AMI onset which was higher than normal [22]. This work was been
carried out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) and approved by
Brawijaya University- Dr. Saiful Anwar Hospital Ethics Committee.
2.4. Immunization and ELISA
Immunization was performed by injecting 100 ul of the Lp-PLA2
proteins (variants 279V and 279F) and supplemented with 100 ul
of adjuvant CFA and IFA (InvivoGen, vac-cfa-10, vac-ifa-10). The
protein was administered intraperitoneally in each group of mice;
groups were injected with Lp-PLA2 variant 279V and 279F, and
adjuvant. The adjuvant used in the initial injection contained CFA
while on subsequent injections IFA was utilized. A booster is given
in the second week after the first injection. The antibody produc-
tion from the mice was measured by the ELISA method, which
was briefly performed as follows: Lp-PLA2 (1 ul) was dissolved
with aquadest (9 ul), then 90 lL coating buffer was added, then
vortexed. The suspension (100 lL) is distributed into a well and
incubated at 4 C overnight. All fluids are aspirated in the well,
then washed using 100 lL PBST (Biorad, Bioworld) for 3 consecu-
tive times. Following this, 100 lL blocking buffer BSA 1% (Promega)
was added to the well and incubated for 1 h at room temperature.
Afterward, the well was washed using 100 lL PBST 3 times for
3 min. 100 lL of primary antibodies (serum mouse dissolved with
PBS of 1: 500) was then poured into the well and incubated for 1 h
at 25 C. The well was then washed using 100 lL PBST at 0.2% 3
times for 3 min. Therefore, 100 lL of secondary antibody (Antibody
Goat anti-mouse IgG Antibody HRP conjugated: 1000  dilution)
(Rockland, 610-1319-0500) was added to the well and incubated
for 1 h at 25 C. The post incubation well was washed using
100 lL PBST 0.2% 3 times for 3 min. Subsequently, TMB substrate
was added (BioLegend, B218177) into the well and incubated for
30 min at room temperature. The reaction was discontinued by
adding 50 lL stop solution (Cusabio, 140652) without removing
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ELISA Reader at 450 nm wavelength.Table 1
The different profile of 279V and 279F protein variants of Lp PLA2.
No Character Wildtype (279V) Mutant (279F)
1 Hydrophobicity amino acid no 279 2.8 4.2
2 Energy stability (kcal/mol) 46.62 -49.76
3 Mass (g/mol) 42156.953 40087.340
4 Accessible surface area 14506.01 Å2 14671.75 Å23. Results
The role of the PLA2G7 gene or Lp-PLA2 protein in the humans’
biological processes has been assessed by using protein-protein
interactions based on three protein-protein interaction databases,
i.e., STRING, MENTHA and the BIOGRID database. The results of this
study exhibited that Lp-PLA2 proteins were observed to interact
with various proteins including CCL24, CCL26, ESR1 and FADH pro-
teins associated with lipid metabolism. However, Lp-PLA2 proteins
also play a role as molecules involved in the inflammatory
response (Fig. 1). This data is in line with previous research stating
that the Lp-PLA2 protein contributes to the process of splitting oxi-
dized lipids into compounds that are capable of stimulating the
immune system [21]. In the case of atherosclerosis, this protein
is secreted by macrophages to attract immune cells to eliminate
oxidized lipids in blood vessel tissue. However, excessive activa-
tion may increase inflammation that may eventually increase the
arteriosclerosis process.
The data on protein-protein interactions indicated that Lp-PLA2
is involved in the inflammatory process. This process of inflamma-
tion is an important process that takes place in atherosclerosis and
AMI. This phenomenon supported a previous report indicating that
the Lp-PLA2 protein plays a major role in the inflammation process
leading to a heart attack [9,19]. Our previous study found that the
Val279Phe (V279F) polymorphism of Lp-PLA2 was affecting bothFig. 1. PLA2G7 has a role in various biological processes. The PLA2G7-connected genes
extracted based on the genes that directly connect to PLA2G7; PLA2G2D, CCL26, UBC, LD
has a role in the process of wound healing, stress response defense response and inflamprotein folding and enzymatic activity. This polymorphism was
identified as leading to different outcomes of AMI events in the
Indonesian subpopulation. Therefore we performed analysis on
the hydrophobicity, energy stability, and accessible surface area
to find out whether V279F polymorphisms changed the properties
of the Lp-PLA2 proteins or not. The analysis results indicate that
the Lp-PLA2 variant 279F increased hydrophobicity and accessible
surface area, while the variant 279F reduced the energy stability
(Table 1). These data suggest that the 279F variant has better sta-
bility and accessible surface area to contact with another molecule
compared to 279V.
Based on the analysis, the V279F polymorphism exhibits a dif-
ferent protein profile, which will likely cause changes in structure,
antigenicity, and epitopes. The structured profile of the Lp-PLA2
protein was then examined using the FoldX software. The data sug-
gested that the polymorphism in Lp-PLA2 changed the angle and
orientation of the side chains of some of the amino acids. These
changes to the side group orientations might also have an impact
on the molecular surface (Fig. 2). This phenomenon is likely toare identified in the STRING, MENTHA and BIOGRID databases (A), which are then
L-PLA2, CCL24, PLA2G2E, ESR1, and FADH. (B) Based on the network genes, PLA2G7
mation (C & D).
B C A 
Fig. 2. The V279F polymorphism might change the profile of the Lp-PLA2 protein. The protein Lp-PLA2 variant 279F, green (A), and variant 279F, red (B); with a difference in
surface structure (C); resulting in changes of hydrophobicity, energy stability, and surface area of the V279F polymorphism.
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the protein stability of the Lp-PLA2 protein.
Further analysis was performed to predict epitope in both vari-
ants of Lp-PLA2. This analysis was conducted to observe whether
the V279F polymorphism will cause an epitope shift or not. This
information is crucial for identifying the specific epitope for the
two variants of the proteins, which could be used to develop mon-
oclonal antibodies to distinguish 279V from 279F variants specifi-
cally. The results of this study indicate that the variant V279F of
Lp-PLA2 causes epitope shift (Table 2). We identified 15 epitopes
in both variants, with two of the epitopes being peculiar to each
variant. Epitope no. 15 is a specific epitope for the Lp-PLA2 variant
of 279F, while epitope no. 13 can be developed specifically for a
279V variant of Lp-PLA2. These results are essential for the devel-
opment of monoclonal antibody for human diagnosis of Lp-PLA2
variants. Moreover, the epitope shift might also influence the
immune system response.
Furthermore, we isolated both types of variants of Lp-PLA2 from
patients of heart disease. The protein was then injected in mice
(Mus musculus) to determine the B cells response in producing
IgG. The results of this study indicate that these two variants cause
different IgG production responses in mice (Fig. 3). The 279F vari-
ant of Lp-PLA2 has the ability to induce better IgG productivity
compared to the 279V variant. This protein is also seen to be cap-
able of inducing IgG production after one week of injection in mice.Table 2
The V279F shifted epitope of Lp-PLA2 protein.
No Start End Residues
1 72 78 FDHTNKG
2 87 95 SQDNDRLD
3 108 128 SKFLGTHW
4 135 144 NSPLRPGEK
5 132 144 ANWNSPLR
6 189 202 YFKDQSAAE
7 205 220 YLRTLKQEE
8 238 266 DIDHGKPVK
9 284 288 SEDQR
10 302 312 LGDEVYSRI
11 319 341 SEYFQYPAN
12 360 376 ATGKIIGHM
13 396 424 LGLHKDFDQ
14 396 407 LGLHKDFDQ
15 409 424 IEGDDENLIP4. Discussion
The results suggested that Lp-PLA2 plays a role in inflammation,
which is a link to the atherosclerotic process. This data corresponds
with a previous report indicating that the protein has a correlation
to the process of cardiovascular atherosclerosis which in turn is
known to lead to a heart attack [1,9,19]. Moreover, the polymor-
phism in these proteins could influence the process of AMI [13].
The well-known V279F polymorphism of Lp-PLA2 has a significant
effect on protein function that may also have implications for car-
diovascular diseases. Moreover, this polymorphism also has a
major role in triggering the risk of heart attacks [14,32]. Substitut-
ing the amino acid at position 279 from Valine to Phenylalanine
may cause a change in protein folding and enzymatic activity
and therefore affecting catalysis of its substrate. This also has an
effect on the risk of a heart attack (AMI) [18,22]. Although there
are several different arguments regarding V279F; some argue that
the 279 F variant is protective, while some express it as an inductor
of AMI [19,20,22].
Thus, analysis of the structure and epitope was performed on
both Lp-PLA2 protein variants. The results of this study indicate
that the changes at amino acid position 279 from Valine to Pheny-
lalanine led to stimulating better energy stability, epitope shift and
the emergence of the new epitope. This result suggests that amino
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Fig. 3. The Lp-PLA2 (55 kDa) protein was isolated from human serum (A), which was then used for immunization in mice. The immunization results illustrated that Lp-PLA2
with the 279F variant had the ability to stimulate IgG production better than the 279V variant (B).
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shift due to the 279F variant were estimated to increase the
immunogenicity, which can stimulate better IgG production com-
pared to the 279V variant.
Moreover, the substitution of amino acid number 279 from
valine into phenylalanine may result in a change to protein struc-
ture which is implicated in the reduction of its enzymatic activity –
the cutting of its substrate, the oxidized lipids. The lowered
enzyme activity was assumed to reduce the inflammatory
response in the arterial tissue leading to a deceleration in
atherosclerosis progression. Overall, this study is likely to open
up new research opportunities for developing antibodies that are
capable of detecting these two variants specifically. The specific
antibody could be used to detect these two alternatives of Lp-
PLA2, which is important for determining the risk of AMI at earlier
stages.
5. Conclusion
The V279F polymorphism of the Lp-PLA2 protein changes the
protein profile, energy stability, and epitope shift. The polymor-
phisms led to differences in their ability to induce IgG production
in mice. The 279F variant demonstrated better protein stability
and was able to induce higher IgG production compared with the
279V variant. The study will open new directions for developing
a monoclonal antibody that is able to distinguish the two variants
specifically, which is a warrant for further development of AMI risk
factor prediction.
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